Business Context and Reporting Period
This Form 8-K Current Report is filed by Acadia Pharmaceuticals Inc. on April 27, 2026, with the report date finalized on April 30, 2026. The filing primarily addresses a significant executive departure within the company's leadership team.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Executive Departure: Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, has announced her planned retirement for personal reasons.
- Transitional Plan: Dr. Thompson will continue in her current role until a successor is appointed.
- Consulting Role: Following the appointment of a successor, she intends to remain as a consultant through the end of 2026.
- Strategic Continuity: Her continued involvement is specifically noted to support the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer's disease psychosis.
- Recruitment: The Company has initiated a search for Dr. Thompson's replacement.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding Dr. Thompson's anticipated retirement timeline, her continued service during the transition, and the search for a new Head of Research and Development. The Company notes that actual results may differ materially from these expectations due to various risks and uncertainties, including the potential for Dr. Thompson to continue serving in her role beyond current plans. No specific financial guidance or new risk factors unrelated to this personnel change are disclosed in this document.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Head of Research and Development.
- Confirm the specific terms of Dr. Thompson's consulting agreement post-transition.
- Monitor upcoming updates regarding the Phase 2 clinical study readout for remlifanserin in Alzheimer's disease psychosis.
- Review the press release dated April 30, 2026 (Exhibit 99.1) for additional details on the retirement announcement.